How COVID-19 Is Driving RWE Uptake In Clinical Trials
Executive Summary
With the COVID-19 pandemic exacerbating the challenges of recruiting patients for studies targeting catastrophic diseases and rare cancers, regulators are becoming more receptive to new ways of using real-world evidence in clinical trials.
You may also be interested in...
Real-World Data: ‘Don’t Take Your Foot Off The Gas’
It is possible to maintain the current focus on the use of real-world data in drug development by finding simple solutions to existing challenges, argues an expert at a US-based RWD platform.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.